SCHEMBL6114278

SCHEMBL6114278

CCS(=O)(=O)c1ccc(OC)c(N(S)C(N)=O)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.45
▸ HCRTR2 O43614 1/20 0.42
▸ DRD2 P14416 3/20 0.41
▸ DRD3 P35462 3/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ BRD4 O60885 1/20 0.41
▸ FLT1 P17948 1/20 0.41
▸ FLT4 P35916 1/20 0.41
▸ KDR P35968 1/20 0.41
▸ POLB P06746 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ PKM P14618 1/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ PAX8 Q06710 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6114373 0.86 SMN1; SMN2 (0.50) HPGDDRD2DRD3ALDH1A1POLB
SCHEMBL6114258 0.77 HPGD (0.51) HPGDALDH1A1TSHRMEN1KMT2A
SCHEMBL20892712 0.76 MAPK1 (0.68) DRD2DRD3BRD4POLBTSHR
SCHEMBL2348770 0.76 GAA (0.51) DRD2DRD3ALDH1A1BRD4FLT1
SCHEMBL4923833 0.76 HTT (0.49) ALDH1A1PKMMEN1KMT2A
SCHEMBL3039158 0.76 SLC9A1 (0.41) HPGDALDH1A1POLBTSHR
SCHEMBL14053273 0.76 CYP1A2 (0.42) TSHRMAPK1MEN1KMT2ACA12
SCHEMBL29622774 0.76 GAA (0.51) DRD2DRD3ALDH1A1BRD4FLT1
SCHEMBL6113827 0.74 ALDH1A1 (0.54) ALDH1A1POLBMAPK1PKMMEN1
SCHEMBL3044568 0.73 ALDH1A1 (0.43) ALDH1A1TSHRMEN1KMT2ACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 — — US disclosed
WO-2012068209-A2 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA NV (BE) 2012-05-24 — — WO disclosed
WO-2012068210-A1 PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA NV (BE) 2012-05-24 — — WO disclosed
US-20120129843-A1 PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129843-A1 PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION MMP1, MMP9, TIMP3 HPGD 272/4885HCRTR2 4472/4885DRD2 2598/4885
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION MMP1, MMP9, MMP2 HPGD 739/4885HCRTR2 3886/4885DRD2 2368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback